1043429-53-3

Upstream product

• 20451-53-0 Phenyl vinyl sulfoxide 
• 140848-63-1 N-Methyl-2-(phenylsulfinyl)ethylamine 
• 1043429-51-1 N-(2-benzenesulfinylethyl)-3-hydroxy-4-methoxy-N-methylbenzamide 
• 100-39-0 benzyl bromide 

Downstream Products

• 1043429-13-5 6-methoxy-7-(3-methoxybenzyloxy)-2-methylisoquinolin-1(2H)-one 
• 1043429-15-7 7-(3,5-dimethoxybenzyloxy)-6-methoxy-2-methylisoquinolin-1(2H)-one 
• 1043429-19-1 5-benzyloxyl-6-methoxy-2-methylisoquinolin-1(2H)-one 
• 1043429-23-7 6-methoxy-5-(3-methoxybenzyloxy)-2-methyl-2H-isoquinolin-1-one 
• 1043429-21-5 5-(3,5-dimethoxybenzyloxy)-6-methoxy-2-methylisoquinolin-1(2H)-one 

Relevant academic research and scientific papers

Synthesis and functional characterization of substituted isoquinolinones as MT2-selective melatoninergic ligands

series of substituted isoquinolinones were synthesized and their binding affinities and functional activities towards human melatonin MT1 and MT2 receptors were evaluated. Structure-activity relationship analysis revealed that substituted isoquinolinones bearing a 3-methoxybenzyloxyl group at C5, C6 or C7 position respectively (C5.C6.C7 in terms of their potency) conferred effective binding and selectivity toward the MT2 receptor, with 15b as the most potent compound. Most of the tested compounds were MT2-selective agonists as revealed in receptormediated cAMP inhibition, intracellular Ca2+ mobilization and phosphorylation of extracellular signal-regulated protein kinases. Intriguingly, compounds 7e and 7f bearing a 4-methoxybenzyloxyl group or 4-methylbenzyloxyl at C6 behaved as weak MT2-selective antagonists. These results suggest that substituted isoquinolinones represent a novel family of MT2-selective melatonin ligands. The position of the substituted benzyloxyl group, and the substituents on the benzyl ring appeared to dictate the functional characteristics of these compounds. Copyright:

ISOQUINOLONE COMPOUNDS AS SUBTYPE-SELECTIVE AGONISTS FOR MELATONIN RECEPTORS MT1 AND MT2

A method of treating, preventing, or ameliorating a pathological condition associated with a melatonin receptor in a mammal by using a pharmaceutical composition containing a compound of formula (I) as a ligand interacting with the melatonin receptor, Rs

ISOQUINOLONE COMPOUNDS AS SUBTYPE-SELECTIVE AGONISTS FOR MELATONIN RECEPTORS MT1 AND MT2

A method of treating, preventing, or ameliorating a pathological condition associated with a melatonin receptor in a mammal by using a pharmaceutical composition containing a compound of formula (I) as a ligand interacting with the melatonin receptor, (I)